263 related articles for article (PubMed ID: 8631555)
21. Late effects of post-high-dose-rate brachytherapy for oropharyngeal carcinoma: are they severer than post-low-dose-rate?
Nose T; Peiffert D; Lapeyre M; Hoffstetter S; Koizumi M; Nishiyama K
Strahlenther Onkol; 2004 Dec; 180(12):776-82. PubMed ID: 15592697
[TBL] [Abstract][Full Text] [Related]
22. High versus low dose rate intracavitary irradiation for adenocarcinoma of the uterine cervix.
Kim WC; Kim GE; Suh CO; Loh JJ
Jpn J Clin Oncol; 2001 Sep; 31(9):432-7. PubMed ID: 11689597
[TBL] [Abstract][Full Text] [Related]
23. Optimization and it's influence on value of doses in HDR and PDR brachytherapy.
Skowronek J; Zwierzchowski G; Piotrowski T; Milecki P
Neoplasma; 2010; 57(4):369-76. PubMed ID: 20429630
[TBL] [Abstract][Full Text] [Related]
24. Brachytherapy for carcinoma of the cervix: a Canadian survey of practice patterns in a changing era.
Pearce A; Craighead P; Kay I; Traptow L; Doll C
Radiother Oncol; 2009 May; 91(2):194-6. PubMed ID: 18922592
[TBL] [Abstract][Full Text] [Related]
25. The optimal fraction size in high-dose-rate brachytherapy: dependency on tissue repair kinetics and low-dose rate.
Sminia P; Schneider CJ; Fowler JF
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):844-9. PubMed ID: 11849810
[TBL] [Abstract][Full Text] [Related]
26. Treatment planning for MRI assisted brachytherapy of gynecologic malignancies based on total dose constraints.
Lang S; Kirisits C; Dimopoulos J; Georg D; Pötter R
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):619-27. PubMed ID: 17869676
[TBL] [Abstract][Full Text] [Related]
27. Primary radiotherapy of stage IIA/B-IIIB cervical carcinoma. A comparison of continuous versus sequential regimens.
Mayer A; Nemeskéri C; Petneházi C; Borgulya G; Varga S; Naszály A
Strahlenther Onkol; 2004 Apr; 180(4):209-15. PubMed ID: 15057431
[TBL] [Abstract][Full Text] [Related]
28. Salvage high-dose-rate (HDR) brachytherapy for recurrent head-and-neck cancer.
Hepel JT; Syed AM; Puthawala A; Sharma A; Frankel P
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1444-50. PubMed ID: 16029806
[TBL] [Abstract][Full Text] [Related]
29. [Gynecologic brachytherapy--from low-dose-rate to high-tech].
Herrmann T; Christen N; Alheit HD
Strahlenther Onkol; 1993 Mar; 169(3):141-51. PubMed ID: 8465248
[TBL] [Abstract][Full Text] [Related]
30. Pulsed dose rate and fractionated high dose rate brachytherapy: choice of brachytherapy schedules to replace low dose rate treatments.
Visser AG; van den Aardweg GJ; Levendag PC
Int J Radiat Oncol Biol Phys; 1996 Jan; 34(2):497-505. PubMed ID: 8567354
[TBL] [Abstract][Full Text] [Related]
31. Radiobiological modelling of dose-gradient effects in low dose rate, high dose rate and pulsed brachytherapy.
Armpilia C; Dale RG; Sandilos P; Vlachos L
Phys Med Biol; 2006 Sep; 51(17):4399-411. PubMed ID: 16912389
[TBL] [Abstract][Full Text] [Related]
32. Radical radiotherapy with high-dose-rate brachytherapy for uterine cervix cancer long-term results.
Khor TH; Tuan JK; Hee SW; Tham IW
Australas Radiol; 2007 Dec; 51(6):570-7. PubMed ID: 17958695
[TBL] [Abstract][Full Text] [Related]
33. Is there a radiobiologic basis for improving the treatment of advanced stage cervical cancer?
Lindegaard JC; Overgaard J; Bentzen SM; Pedersen D
J Natl Cancer Inst Monogr; 1996; (21):105-12. PubMed ID: 9023838
[TBL] [Abstract][Full Text] [Related]
34. Dosimetric parameters that predict late rectal complications after curative radiotherapy in patients with uterine cervical carcinoma.
Hyun Kim T; Choi J; Park SY; Lee SH; Lee KC; Yang DS; Shin KH; Cho KH; Lim HS; Kim JY
Cancer; 2005 Sep; 104(6):1304-11. PubMed ID: 16078262
[TBL] [Abstract][Full Text] [Related]
35. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
[TBL] [Abstract][Full Text] [Related]
36. [Clinical evaluation based on cost-effectiveness].
Inoue T; Inoue T
Gan To Kagaku Ryoho; 1998 Jan; 25(1):13-9. PubMed ID: 9464324
[TBL] [Abstract][Full Text] [Related]
37. Dosimetric and radiobiological comparison of volumetric modulated arc therapy, high-dose rate brachytherapy, and low-dose rate permanent seeds implant for localized prostate cancer.
Yang R; Zhao N; Liao A; Wang H; Qu A
Med Dosim; 2016; 41(3):236-41. PubMed ID: 27400663
[TBL] [Abstract][Full Text] [Related]
38. Concurrent chemoradiotherapy using high-dose-rate intracavitary brachytherapy for uterine cervical cancer.
Toita T; Moromizato H; Ogawa K; Kakinohana Y; Maehama T; Kanazawa K; Murayama S
Gynecol Oncol; 2005 Mar; 96(3):665-70. PubMed ID: 15721409
[TBL] [Abstract][Full Text] [Related]
39. Comparison of high-dose-rate and low-dose-rate brachytherapy in the treatment of endometrial carcinoma.
Fayed A; Mutch DG; Rader JS; Gibb RK; Powell MA; Wright JD; Elnaqa I; Zoberi I; Grigsby PW
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):480-4. PubMed ID: 17141980
[TBL] [Abstract][Full Text] [Related]
40. [Present and future in brachytherapy--from the discovery of radium to the 21st century].
Inoue T; Inoue T
Gan To Kagaku Ryoho; 1999 Aug; 26(9):1254-60. PubMed ID: 10478177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
